J&J settles Amgen clash over psoriasis drug

Amgen can market a biosimilar version of Stelara from January 2025 after J&J resolved its infringement lawsuit that centred on two Stelara patents.

Fed Circ refutes Medtronic challenge

A prior art reference does not qualify, says the Federal Circuit, dashing the firm’s hope to invalidate five catheter technology patents.

Effects of GSK v Teva ripple as SCOTUS denies cert

Lawyers from Axinn, Veltrop & Harkrider explore a case that could have major implications for generic drugs, biosimilars, and how skinny labels are read.

Latest news